Search - tctmd.com

Displaying 1 - 20 of 329

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Biggest News of 2025

Michael O'Riordan

January 01, 2026

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

Caitlin E. Cox

December 01, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Daily News

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Yael L. Maxwell

October 24, 2025

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Daily News

Pregnancy-Related CV Complications on the Rise

Todd Neale

October 09, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

News Daily News

AI Tool Supports Mammograms as Method to Screen Women for CV Risk

Caitlin E. Cox

September 18, 2025

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Opinion CV Team Dispatch

August 2025 Dispatch for the CV Team

L.A. McKeown

August 22, 2025

News Daily News

DAPT De-escalation Success Varies by Sex: Meta-analysis

Yael L. Maxwell

August 21, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

Advertisement

TCTMD’s Biggest News of 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

TCTMD’s Top 10 Most Popular Stories for November 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

What’s Going to Be Hot at TCT 2025

Pregnancy-Related CV Complications on the Rise

Evolocumab Wins for Primary Prevention in VESALIUS-CV

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

AI Tool Supports Mammograms as Method to Screen Women for CV Risk

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Evolocumab Gains Expanded Indication for Primary Prevention

August 2025 Dispatch for the CV Team

DAPT De-escalation Success Varies by Sex: Meta-analysis

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content